SCHEMBL7337441

SCHEMBL7337441

COc1ccc2ccc(C#N)cc2c1-c1ccoc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 3/20 0.60
F2 P00734 1/20 0.60
PLG P00747 1/20 0.60
PLAT P00750 1/20 0.60
KLK1 P06870 1/20 0.60
PRSS1 P07477 1/20 0.60
LRRK2 Q5S007 2/20 0.42
AR P10275 3/20 0.38
ACHE P22303 1/20 0.37
MAPT P10636 2/20 0.36
KDM1A O60341 1/20 0.36
GAK O14976 1/20 0.36
RIPK2 O43353 1/20 0.36
COQ8A Q8NI60 1/20 0.36
NLK Q9UBE8 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7720382 0.81 MAPT (0.47) ARACHEMAPTMEN1LMNA
SCHEMBL26260067 0.76 F2 (0.58) PLAUF2PLGPLATKLK1
SCHEMBL7338518 0.76 PLAU (0.60) PLAUARACHEMAPTKDM4E
SCHEMBL7337455 0.75 PLAU (0.61) PLAUARPDE5A
SCHEMBL7344275 0.73 MAPT (0.47) PLAUARACHEMAPTMEN1
SCHEMBL7723749 0.72 AR (0.50) ARACHEKDM1AGAKRIPK2
SCHEMBL7337530 0.72 AR (0.46) ARACHEMAPTKDM1AGAK
SCHEMBL7344856 0.71 AR (0.45) ARACHEKDM1AGAKRIPK2
SCHEMBL7336198 0.71 AR (0.45) ARACHEMAPTKDM1AGAK
SCHEMBL7341643 0.71 AR (0.45) ARACHEKDM1AGAKRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed
EP-0819125-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-01-21 EP disclosed
WO-1996031492-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1996-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885F2 38/4885PLG 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.